IN8bio, Inc. (INAB)

NASDAQ: INAB · IEX Real-Time Price · USD
2.30
0.00 (0.00%)
At close: Jan 31, 2023, 12:00 AM
2.32
+0.02 (1.05%)
After-hours: Jan 31, 2023, 4:00 PM EST
Market Cap 57.34M
Revenue (ttm) n/a
Net Income (ttm) -26.57M
Shares Out 24.50M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 221
Open 2.31
Previous Close 2.30
Day's Range 2.21 - 2.36
52-Week Range 1.38 - 4.98
Beta n/a
Analysts Buy
Price Target 13.26 (+477.53%)
Earnings Date Mar 16, 2023

About INAB

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 26
Stock Exchange NASDAQ
Ticker Symbol INAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for INAB stock is "Buy." The 12-month stock price forecast is $13.26, which is an increase of 477.53% from the latest price.

Price Target
$13.26
(477.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IN8bio to Present at the B. Riley Securities' 3rd Annual Virtual Oncology Conference

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced ...

2 weeks ago - GlobeNewsWire

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a clinical updat...

3 weeks ago - GlobeNewsWire

IN8bio to Present at Biotech Showcase 2023 in San Francisco

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced ...

1 month ago - GlobeNewsWire

IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100

NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated results ...

1 month ago - GlobeNewsWire

IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that it has rece...

1 month ago - GlobeNewsWire

IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its ...

2 months ago - GlobeNewsWire

IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its ...

3 months ago - GlobeNewsWire

IN8bio to Present at November Investor Conferences

NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its ...

3 months ago - GlobeNewsWire

IN8bio to Present at Cantor Oncology & HemOnc Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its...

4 months ago - GlobeNewsWire

IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400

NEW YORK and LOUISVILLE, Ky, Sept. 15, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapi...

4 months ago - GlobeNewsWire

IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its...

5 months ago - GlobeNewsWire

IN8bio Appoints Michael R. Bishop, M.D.

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its...

5 months ago - GlobeNewsWire

IN8bio to Present at September Investor and Scientific Conferences

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its ...

5 months ago - GlobeNewsWire

IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering

NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

5 months ago - GlobeNewsWire

IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

6 months ago - GlobeNewsWire

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that u...

6 months ago - GlobeNewsWire

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

6 months ago - GlobeNewsWire

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

6 months ago - GlobeNewsWire

Newly Issued European Patent Broadens IN8bio's Drug Resistant Immunotherapy (DRI) Platform

NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on advancing innovative gamma-delta T cell therapies utilizing its DeltEx pl...

6 months ago - GlobeNewsWire

IN8bio Appoints Kenneth R. LaMontagne, Ph.D.

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

7 months ago - GlobeNewsWire

IN8bio to Present at July Investor and Scientific Conferences

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

7 months ago - GlobeNewsWire

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ...

8 months ago - GlobeNewsWire

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today anno...

8 months ago - GlobeNewsWire

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today annou...

9 months ago - GlobeNewsWire

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies u...

9 months ago - GlobeNewsWire